In the past year, two separate experiments in two different materials captured the same confounding scenario: the coexistence ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. 10 stocks we like better than Structure Therapeutics › Monday ...

A pill from Structure Therapeutics Inc. helped patients lose roughly as much weight as a rival treatment from Eli Lilly & Co., giving the startup an edge as it seeks to break into the highly ...

IN a letter to this journal last week, Mr. Soddy has discussed the bearing of my theory of the nucleus atom on radio-active phenomena, and seems to be under the impression that I hold the view that ...